Vesikari T. ECCMID 2013 abs. O399

1. 1 of 2 Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage (NPC) in children Double-blind, cluster-randomised controlled trial: N=5,023 Finnish children <7 months, randomised to: Pn 3+1: PHiD-CV vaccine: 3 primary doses + booster Control 3+1: Hepatitis B vaccine: 3 primary doses + booster Pn 2+1: PHiD-CV vaccine: 2 primary doses + booster Control 2+1: Hep B vaccine: 2 primary doses + booster Collection of nasopharyngeal swabs: pre-vaccination (N=847 children) + at 4 time points after vaccination PHiD-CV vaccine efficacy: Robust reduction of VT NPC in experimental groups at all timepoints after vaccination (except for 1 month after priming for 2+1 schedule) Mainly reduction of serotypes 6B, 14, 19F and 23F Vesikari T. ECCMID 2013 abs. O399

2. 2 of 2 Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage (NPC) in children Vaccine efficacy (%) at age 18-22 months (7 months after booster)= 1 – relative risk of reducing prevalence of NPC after PHiD-CV vaccine vs control 3+1 schedule 2+1 schedule Vaccination of children with PHiD-CV vaccine may lead to a net reduction in pneumococcal NPC, by substantially reducing VT NPC, while not significantly increasing NPC of NVT or other pathogens Vesikari T. ECCMID 2013 abs. O399